Changes in Hong Kong stocks | Xuanzhu Bio-B (02575) rose more than 20% and then broke the peak. Xuan Yuening entered the medical insurance catalogue and two cancer products were intensively approved during the year

The Zhitong Finance App learned that Xuanzhu Bio-B (02575) rose by more than 20% to a high of HK$93.05, reaching a new listing high. As of press release, it rose 19.51% to HK$92.5, with a turnover of HK$18.775,900.

According to the news, Xuanzhu Biotech recently announced that the innovative drug Xuan Yuening was included in the national basic medical insurance drug catalogue for the first time. The results of this medical insurance negotiation will help the company further improve the affordability and accessibility of Xuan Yuening among patients, further promote the drug's marketing and increase sales scale, and have a positive impact on the company's long-term business development.

The Zhitong Finance App pointed out in “Two Oncology Products Intensively Approved During the Year: Looking at the Innovative Value of Xuanzhu Biology (02575) from the Perspective of Product Power” that in the context of the pharmaceutical industry's return to product power, Xuanzhu Biotech's two new oncology drugs were approved in 2025, completing the key implementation of innovative value. Pirocilil lays out the breast cancer racetrack with “differentiated indications”. Diroac fills the gap in brain metastasis treatment with high intracranial penetrability and over 91% IC-ORR. Both form a “troika” commercialization pattern with aneprazole sodium, laying the core foundation for the company's long-term growth.